Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of PD-1 blockade pembrolizumab for patients with relapsed or refractory Natural Killer(NK)/T Cell Lymphoma.


Clinical Trial Description

Patients with relapsed or refractory NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy. The investigators have been proceeding this trial to evaluate the efficacy and safety of the immune checkpoint inhibitor PD-1 blockade, pembrolizumab in the patients with relapsed or refractory NK/T cell lymphoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03107962
Study type Interventional
Source Zhengzhou University
Contact Mingzhi Zhang, Pro,Dr
Phone 13838565629
Email mingzhi_zhang@126.com
Status Recruiting
Phase Phase 2
Start date February 19, 2017
Completion date December 2018

See also
  Status Clinical Trial Phase
Completed NCT05058755 - Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma N/A
Recruiting NCT06314334 - Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma Phase 2
Completed NCT03618238 - Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma Phase 2
Recruiting NCT04004572 - Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma Phase 2
Recruiting NCT03623087 - SIMPLE Chemotherapy for NK Lymphoma/Leukaemia Phase 3
Recruiting NCT03630731 - Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma Phase 2
Completed NCT03936452 - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma Phase 2
Recruiting NCT04366128 - Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL N/A
Recruiting NCT06376721 - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Phase 1/Phase 2